Clinical trials: Age-Related Maculopathy
- Condition Age-Related Maculopathy
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Macular Degeneration
Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)…
- Trial name
- NCT00845273
- Testing
- Pegaptanib sodium
- Volunteers
- 3,538 people
- Sponsor
- Pfizer
Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
This is a prospective pilot study to evaluate the usability and applicability of a self monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age Related Macular…
- Trial name
- NCT01542866
- Testing
- Health Management Tool (HMT)
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
Patient-centred Smartphone AI for Protecting Vision in Macular Disease
Macular disease is the leading cause of blindness in the UK and age-related macular degeneration must undergo monitoring to determine if an injection into the eye is required that month [required in 50% of visits] - these…
- Trial name
- NCT05433766
- Where
- 2 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- OKKO Health
Neovascular Age-Related Macular Degeneration (nAMD)
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD in which they received suprachoroidal…
- Trial name
- NCT05210803
- Testing
- Standard of Care, Ranibizumab
- Where
- 16 sites in United States
- Volunteers
- 116 people
- Sponsor
- AbbVie
Age-Related Macular Degeneration
ForeseeHome NRich Registry
This registry will compare functional and structural data of progression of Intermediate AMD (iAMD) and conversion to neovascular AMD (NV-AMD) while monitored at home with the ForeseeHome Monitoring System (FSH) and during…
- Trial name
- NCT05690880
- Testing
- Foresee Home
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Notal Vision Inc.
Diabetic Retinopathy, Age Related Macular Degeneration
Retinal Care Data Repository
The Retinal Care Data Repository's primary objective is to make data available for Retinal Care to develop algorithms that improve the care of people with retinal diseases.
- Trial name
- NCT04794907
- Testing
- Observation
- Volunteers
- 1,000 people
- Sponsor
- Retinal Care Inc.
Dry Age-related Macular Degeneration, Geographic Atrophy
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.
- Trial name
- NCT01002950
- Testing
- ACU-4429
- Where
- 12 sites in United States
- Volunteers
- 72 people
- Sponsor
- Kubota Vision Inc.
Neovascular Age-Related Macular Degeneration (nAMD), Neovascular (Wet) Age-related Macular Degeneration (AMD)
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage.
- Trial name
- NCT06817343
- Testing
- Aflibercept (2.0 mg)
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Exegenesis Bio
Dry Macular Degeneration
Non Exudative AMD Imaged With SS-OCT- Extension
The investigators wish to better understand the role of the choriocapillaris (CC) in the formation and progression of non-exudative in age related macular degeneration (armd) by imaging the retinal pigment epithelium (rpe) and…
- Trial name
- BIRC-02 (NCT04469140)
- Testing
- SS-OCT imaging
- Where
- 5 sites in United States, Australia
- Volunteers
- 450 people
- Sponsor
- Boston Image Reading Center
Wet Age-related Macular Degeneration (wAMD)
Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word（STONE）
This is a post-marketing drug safety monitoring study in a prospective manner, and data collection will be performed in a registration-follow-up manner.
- Trial name
- NCT03054818
- Where
- 49 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Neovascular Age-related Macular Degeneration
A 52-weeks Observational Study to Evaluate the Safety of Brolucizumab in Patients With nAMD
This study was a prospective, uncontrolled, central registration system, multicenter, domestic observational study (special drug-use surveillance) to evaluate the safety of 52-week clinical treatment with Beovu kit for…
- Trial name
- NCT04632056
- Testing
- Beovu
- Where
- 67 sites in Japan
- Volunteers
- 329 people
- Sponsor
- Novartis Pharmaceuticals
Wet Macular Degeneration
Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
The main objectives of this non-interventional cohort field study are to evaluate effectiveness of Eylea and to describe follow-up as well as treatment patterns in patients with wAMD (wet age-related macular degeneration) in…
- Trial name
- PERSEUS-IT (NCT02289924)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Italy
- Volunteers
- 912 people
- Sponsor
- Bayer
Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO)
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the…
- Conditions
- Age-related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO), Diabetic Macular Edema (DME)
- Trial name
- NCT02585401
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Bayer
Macular Degeneration
EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan
The objective of this survey is to evaluate effectiveness of EYLEA on Quality of Life (QOL). The QOL is evaluated by using Japanese version (v.1.4 - interviewer administered format) of National Eye Institute Visual Function…
- Trial name
- NCT01756261
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 757 people
- Sponsor
- Bayer
Wet Macular Degeneration
Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan
This study aims at investigation of the caregiver burden of Wet Age-related Macular Degeneration (wAMD) patients and at the assessment of how much of caregiver burden could be reduced in transitioning from Pro Re Nata to…
- Trial name
- NCT02541084
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 72 people
- Sponsor
- Bayer
Geographic Atrophy, Macular Degeneration
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a…
- Trial name
- NCT06779773
- Testing
- Avacincaptad pegol (ACP)
- Where
- 58 sites in United States
- Volunteers
- 488 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Macular Degeneration
EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received EYLEA for Age-Related Macular Degeneration (AMD).
- Trial name
- NCT01756248
- Testing
- Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 3,872 people
- Sponsor
- Bayer
Wet Age-related Macular Degeneration
Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration
The study aims to investigate the effectiveness of Eylea in patients with wet age-related macular degeneration in routine clinical practice in Germany.
- Trial name
- PERSEUS (NCT01914380)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Germany
- Volunteers
- 988 people
- Sponsor
- Bayer
AMD
Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD
This is an observational study in which patients affected by dry or wet AMD will be enrolled, after signing the Informed Consent, according to eligibility criteria.
- Trial name
- NCT04177069
- Testing
- Visucomplex Plus
- Where
- 4 sites in Italy
- Volunteers
- 160 people
- Sponsor
- VISUfarma SpA
Neovascular Age-related Macular Degeneration
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
To assess effectiveness of Macugen for treatment of neovascular age-related macular degeneration by measuring the evolution of visual acuity.
- Trial name
- MACURELI (NCT00549055)
- Testing
- Macugen
- Where
- 4 sites in Belgium
- Volunteers
- 38 people
- Sponsor
- Pfizer